# US 2009/0311340 A1 · Use of xenon as neuroprotectant in a neonatal subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0311340 A1
- Document ID: US20090311340A1
- Status: Published application
- Kind: A1
- Application number: 11/667,065
- Filed: 2005-08-19
- Published: 2009-12-17
- Earliest claimed: 2004-08-19
- Assignees: Protexeon Limited
- Inventors: Nicholas Peter Franks; Mervyn Maze
- Web page: https://patentgrep.com/patent/US20090311340A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 23/00: Anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.

## Claims

### Claim at position 1

1-93. (canceled)

### Claim 94

A method of treating, preventing, and/or alleviating anesthetic-induced neurological deficits in a neonatal subject, the method comprising administering a therapeutically effective amount of xenon to said subject.

### Claim 95 (depends on 94)

The method of claim 94, wherein the neurological deficit is associated with neuronal apoptosis, neuronal necrosis, or neuronal injury.

### Claim 96 (depends on 94)

The method of claim 94, wherein the neurological deficit is neurodegeneration.

### Claim 97 (depends on 94)

The method of claim 94, wherein the neurological deficit is a learning, memory, neuromotor, neurocognitive or psychocognitive deficit.

### Claim 98 (depends on 94)

The method of claim 94, wherein the anesthetic is a GABAergic agent.

### Claim 99 (depends on 94)

The method of claim 94, wherein the anesthetic is isoflurane, sevoflurant or desflurane.

### Claim 100 (depends on 94)

The method of claim 94, wherein the anesthetic is isoflurane, the neurological deficit is neuronal injury, and the method further comprises administering isoflurane to the subject.

### Claim 101 (depends on 94)

The method of claim 94, wherein the anesthetic is sevoflurane, the neurological deficit is associated with neuronal injury, and the method further comprising administering sevoflurane.

### Claim 102 (depends on 94)

The method of claim 94, wherein the anesthetic is desflurane, the neurological deficit is associated with neuronal injury, and the method further comprises administering desflurane.

### Claim 103 (depends on 94)

The method of claim 94, wherein the xenon is administered via perfusion.

### Claim 104 (depends on 94)

The method of claim 94, wherein the xenon is in gaseous form.

### Claim 105 (depends on 94)

The method of claim 94, wherein the xenon is administered via inhalation.

### Claim 106

A method of providing anesthesia, neuroprotection, and/or analgesia to a neonatal subject, said method comprising administering xenon in combination with another anesthesia, wherein the amount of xenon is sufficient to alleviate and/or prevent anesthesia-induced neuronal injury.

### Claim 107 (depends on 106)

The method of claim 106, wherein the anesthetic is isoflurane, sevoflurane or desflurane.

### Claim 108 (depends on 106)

The method of claim 106, wherein the xenon is in gaseous form.

### Claim 109 (depends on 106)

The method of claim 106, wherein xenon is administered via inhalation.

### Claim 110 (depends on 106)

The method of claim 106, wherein the xenon is administered via perfusion.

### Claim 111 (depends on 106)

The method of claim 106, further comprising administering a GABAergic agent.

### Claim 112

A method of protecting against hypoxic injury comprising:
administering xenon in combination with an anesthetic.

### Claim 113 (depends on 112)

The method of claim 112, wherein the anesthetic is sevoflurane, isoflurane or desflurane.

### Claim 114 (depends on 112)

The method of claim 112, wherein the anesthetic is sevoflurane and the xenon and the sevoflurane are administered prior to the hypoxic-ischaemic injury.

### Claim 115 (depends on 112)

The method of claim 112, wherein the anesthetic is sevoflurane and the xexon and the sevoflurane are administered at least about two hours prior to the hypoxic-ischaemic injury.

### Claim 116 (depends on 114)

The method of claim 114, wherein the xenon and the sevoflurane are administered from about 2 to about 24 hours prior to the hypoxic-ischaemic injury.

### Claim 117 (depends on 112)

The method of claim 112, wherein the xenon and sevoflurane are administered to the mother prior to delivery, during delivery, prior to a cesarean section, during a cesarean section, or suitable combinations thereof.

### Claim 118

A method of treating, alleviating, and/or preventing neuronal necrosis in a subject, said method comprising administering a therapeutically effective amount of xenon to the patient.
